Loading...
XNASZLAB
Market cap289mUSD
Dec 23, Last price  
26.54USD
1D
-0.67%
1Q
23.04%
IPO
-67.87%
Name

Zai Lab Ltd

Chart & Performance

D1W1MN
XNAS:ZLAB chart
P/E
P/S
10.84
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
12.93%
Rev. gr., 5y
360.03%
Revenues
267m
+24.03%
000129,45212,984,75148,958,000144,312,000215,040,000266,719,000
Net income
-335m
L-30.58%
-18,021,737-37,512,212-50,384,176-139,074,895-183,365,894-298,162,000-692,444,000-481,994,000-334,620,000
CFO
-198m
L-46.09%
-11,464,910-32,158,031-32,367,181-97,538,022-191,011,000-216,055,000-549,231,000-367,642,000-198,178,000
Earnings
Feb 25, 2025

Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
IPO date
Sep 28, 2020
Employees
2,036
Domiciled in
CN
Incorporated in
KY

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
266,719
24.03%
215,040
49.01%
144,312
194.77%
Cost of revenue
643,292
619,397
844,376
Unusual Expense (Income)
NOPBT
(376,573)
(404,357)
(700,064)
NOPBT Margin
Operating Taxes
38,929
(10,970)
Tax Rate
NOPAT
(376,573)
(443,286)
(689,094)
Net income
(334,620)
-30.58%
(481,994)
-30.39%
(692,444)
132.24%
Dividends
Dividend yield
Proceeds from repurchase of equity
(6,433)
(1,730)
814,622
BB yield
2.44%
0.59%
-139.38%
Debt
Debt current
14,208
7,050
5,927
Long-term debt
23,198
33,736
25,153
Deferred revenue
28,738
21,360
27,486
Other long-term liabilities
325
21,360
27,486
Net debt
(778,265)
(974,115)
(1,393,625)
Cash flow
Cash from operating activities
(198,178)
(367,642)
(549,231)
CAPEX
(7,212)
(24,984)
(18,948)
Cash from investing activities
(10,776)
420,016
249,957
Cash from financing activities
(6,433)
(1,730)
820,202
FCF
(366,491)
(463,777)
(700,237)
Balance
Cash
806,451
1,008,470
1,409,100
Long term investments
9,220
6,431
15,605
Excess cash
802,335
1,004,149
1,417,489
Stockholders' equity
(2,158,348)
(1,835,669)
(1,441,713)
Invested Capital
3,005,784
2,931,094
2,883,364
ROIC
ROCE
EV
Common stock shares outstanding
96,639
95,807
92,992
Price
2.73
-10.98%
3.07
-51.15%
6.29
-53.56%
Market cap
264,116
-10.20%
294,127
-49.68%
584,455
-44.40%
EV
(514,149)
(679,988)
(809,170)
EBITDA
(367,544)
(396,130)
(693,577)
EV/EBITDA
1.40
1.72
1.17
Interest
14,582
Interest/NOPBT